Savara Announces Participation in Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in two major healthcare investor conferences in February 2025.

The company's management team will participate in fireside chats at both events:

• The Guggenheim SMID Cap Biotech Conference (February 5-6, 2025), with a fireside chat scheduled for February 5th at 10:00am ET/7:00am PT
• The Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, 2025), with a fireside chat scheduled for February 11th at 8:00am ET/5:00am PT

Live webcasts and replays will be accessible through Savara's corporate website in the 'Events & Presentations' section, remaining available for 90 days.

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.

Guggenheim SMID Cap Biotech Conference, February 5-6, 2025
Fireside Chat: February 5^th, 10:00am ET/7:00am PT

Oppenheimer 35^th Annual Healthcare Life Sciences Conference, February 11-12, 2025
Fireside Chat: February 11^th, 8:00am ET/5:00am PT

The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow^® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma and LinkedIn.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129351153/en/

Media and Investor Relations Contact

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

ir@savarapharma.com

Source: Savara Inc.

FAQ

When is Savara (SVRA) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Savara will present at the Guggenheim SMID Cap Biotech Conference on February 5th, 2025, at 10:00am ET/7:00am PT through a fireside chat.

What time is SVRA's presentation at the Oppenheimer Healthcare Conference 2025?

Savara will present at the Oppenheimer Healthcare Life Sciences Conference on February 11th, 2025, at 8:00am ET/5:00am PT.

How long will SVRA's investor conference webcasts be available for viewing?

The webcasts will be archived and available for viewing on Savara's corporate website for 90 days after the events.

Where can investors watch Savara's (SVRA) February 2025 conference presentations?

Investors can access the live webcasts and replays through the 'Events & Presentations' section of Savara's corporate website at savarapharma.com/investors/events-presentations/.